BiotechTube
Home/Pipeline/A9-3408

A9-3408

Not Specified

Phase 1Active

Key Facts

Indication
Not Specified
Phase
Phase 1
Status
Active
Company
Alpha-9 Oncology

About Alpha-9 Oncology

Alpha-9 Oncology is a private, clinical-stage biotech pioneering next-generation radiopharmaceuticals for cancer. Spun out from the University of British Columbia and BC Cancer, the company leverages a proprietary, iterative design platform to create targeted therapies using isotopes like Actinium-225 and Lutetium-177. With a pipeline advancing into Phase 1 trials, strategic isotope supply agreements, and backing from top-tier investors following a Series C in 2024, Alpha-9 is positioned to accelerate the development of precision oncology treatments. The company operates dual R&D facilities in Vancouver and a corporate office in Boston.

View full company profile

Therapeutic Areas

Oncology

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved